ZOVIRAX CREAM 5% ww

País: Cingapura

Língua: inglês

Origem: HSA (Health Sciences Authority)

Ingredientes ativos:

ACYCLOVIR

Disponível em:

GLAXOSMITHKLINE PTE LTD

Código ATC:

D06BB03

Dosagem:

5% w/w

Forma farmacêutica:

CREAM

Composição:

ACYCLOVIR 5% w/w

Via de administração:

TOPICAL

Tipo de prescrição:

Prescription Only

Fabricado por:

GLAXO WELLCOME OPERATIONS

Status de autorização:

ACTIVE

Data de autorização:

1988-05-14

Folheto informativo - Bula

Singapore proposed PI_clean 

_ZOVIRAX_ 
TM

 CREAM 
QUALITATIVE AND QUANTITATIVE COMPOSITION 
Cream containing 5% w/w acyclovir 
PHARMACEUTICAL FORM 
Cream 
CLINICAL PARTICULARS 
INDICATIONS 
_ZOVIRAX _Cream is indicated
for the treatment of _herpes simplex_ virus infections of the skin 
including initial and
recurrent genital herpes and _herpes labialis. _
DOSAGE AND ADMINISTRATION 
Adults and children:- 
_ZOVIRAX_ Cream should be applied
five times daily at approximately 4-hourly intervals omitting 
the night time dose. 
_ZOVIRAX_ Cream should be applied to
the lesions or impending lesions as early as possible after 
the start of an infection. It is particularly important to start
treatment of recurrent episodes during 
the prodromal period or when the lesions first appear. 
Treatment should be continued for 5
days. If healing has not occurred treatment may be 
continued for up to 10 days. 
CONTRA-INDICATIONS 
_ZOVIRAX_  Cream is contra-indicated in patients known to
be hypersensitive to acyclovir, 
valacyclovir,
propylene glycol or any of the excipients of _ZOVIRAX_ Cream. 

SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE 
_ZOVIRAX_  Cream is not recommended for application to
mucous membranes, such as in the 
mouth, eye or vagina, as it may be irritant.
Particular care should be taken to avoid accidental 
introduction into the eye. 
In severely immune-compromised patients (e.g.
AIDS patients or bone marrow transplant 
recipients) oral _ZOVIRAX_  dosing should be considered. Such
patients should be encouraged to 
consult a physician
concerning the treatment of any infection. 
DRUG INTERACTIONS 
No clinically significant interactions have been identified. 
USE IN PREGNANCY AND LACTATION 
A post-marketing acyclovir pregnancy registry has documented
pregnancy outcomes in women 
exposed to any formulation o

Características técnicas

Singapore proposed PI_clean
_ZOVIRAX_
TM CREAM
QUALITATIVE AND QUANTITATIVE COMPOSITION
Cream containing 5% w/w acyclovir
PHARMACEUTICAL FORM
Cream
CLINICAL PARTICULARS
INDICATIONS
_ZOVIRAX _
Cream is indicated for the treatment of
_herpes simplex_
virus infections of the skin
including initial and recurrent genital herpes and
_herpes labialis. _
DOSAGE AND ADMINISTRATION
Adults and children:-
_ZOVIRAX_
Cream should be applied five times daily at approximately 4-hourly
intervals omitting
the night time dose.
_ZOVIRAX_
Cream should be applied to the lesions or impending lesions as early
as possible after
the start of an infection. It is particularly important to start
treatment of recurrent episodes during
the prodromal period or when the lesions first appear.
Treatment should be continued for 5 days. If healing has not occurred
treatment may be
continued for up to 10 days.
CONTRA-INDICATIONS
_ZOVIRAX_
Cream is contra-indicated in patients known to be hypersensitive to
acyclovir,
valacyclovir, propylene glycol or any of the excipients of
_ZOVIRAX_
Cream.
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
_ZOVIRAX_
Cream is not recommended for application to mucous membranes, such as
in the
mouth, eye or vagina, as it may be irritant. Particular care should be
taken to avoid accidental
introduction into the eye.
In severely immune-compromised patients (e.g. AIDS patients or bone
marrow transplant
recipients) oral
_ZOVIRAX_
dosing should be considered. Such patients should be encouraged to
consult a physician concerning the treatment of any infection.
DRUG INTERACTIONS
No clinically significant interactions have been identified.
USE IN PREGNANCY AND LACTATION
A post-marketing acyclovir pregnancy registry has documented pregnancy
outcomes in women
exposed to any formulation of
_ZOVIRAX_
. The registry findings have not shown an increase in
the number of birth defects amongst
_ZOVIRAX_
exposed subjects compared with the general
population, and any birth defects showed no uniqueness or consistent
pattern to suggest a
com